3-Methylthiofentanyl

3-Methylthiofentanyl
Clinical data

Other names	N-[3-methyl-1-(2-thiophen-2-ylethyl)-4-piperidyl]-N-phenyl-propanamide; 3-methyl-thiofentanyl
Legal status
Legal status	BR: Class F1 (Prohibited narcotics) CA: Schedule I DE: Anlage I (Authorized scientific use only) UK: Class A US: Schedule I
Identifiers
IUPAC name (RS)-N-{3-Methyl-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide
CAS Number	86052-04-2^N
PubChem CID	62296
DrugBank	DB01439^Y
ChemSpider	56092^Y
UNII	C9C204973M
KEGG	C22790
ChEBI	CHEBI:53763^Y
Chemical and physical data
Formula	C₂₁H₂₈N₂OS
Molar mass	356.53 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES O=C(N(c1ccccc1)C2CCN(CC2C)CCc3sccc3)CC
InChI InChI=1S/C21H28N2OS/c1-3-21(24)23(18-8-5-4-6-9-18)20-12-14-22(16-17(20)2)13-11-19-10-7-15-25-19/h4-10,15,17,20H,3,11-14,16H2,1-2H3^Y Key:SRARDYUHGVMEQI-UHFFFAOYSA-N^Y
^NY (what is this?) (verify)

3-Methylthiofentanyl is an opioid analgesic and analogue of fentanyl.

3-Methylthiofentanyl was sold briefly on the black market in the early 1980s, before the introduction of the Federal Analogue Act which for the first time attempted to control entire families of drugs based on their structural similarity rather than scheduling each drug individually as they appeared.^[1]

3-Methylthiofentanyl has similar effects to fentanyl. Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.^[2]

References

^ Henderson, GL (1988). "Designer Drugs: Past History and Future Prospects". Journal of Forensic Sciences. 33 (2): 569–575. doi:10.1520/JFS11976J. PMID 3286815.
^ Mounteney J, Giraudon I, Denissov G, Griffiths P (July 2015). "Fentanyls: Are we missing the signs? Highly potent and on the rise in Europe". The International Journal of Drug Policy. 26 (7): 626–631. doi:10.1016/j.drugpo.2015.04.003. PMID 25976511.